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Abstract
Background: The molecular biology of renal cell carcinoma (RCC) is complex and not fully understood. We have recently
found that the expression of the receptor tyrosine kinase Axl in the RCC tumors independently correlates with survival of
the patients.
Principal Findings: Here, we have investigated the role of Axl and its ligand Gas6, the vitamin-K dependent protein product
of the growth arrest-specific gene 6, in clear cell RCC (ccRCC) derived cells. The Axl protein was highly expressed in ccRCC
cells deficient in functional von Hippel-Lindau (VHL) protein, a tumor suppressor gene often inactivated in ccRCC. VHL
reconstituted cells expressed decreased levels of Axl protein, but not Axl mRNA, suggesting VHL to regulate Axl expression.
Gas6-mediated activation of Axl in ccRCC cells resulted in Axl phosphorylation, receptor down-regulation, decreased cell-
viability and migratory capacity. No effects of the Gas6/Axl system could be detected on invasion. Moreover, in ccRCC tumor
tissues, Axl was phosphorylated and Gas6 c-carboxylated, suggesting these molecules to be active in vivo.
Significance: These results provide novel information regarding the complex function of the Gas6/Axl system in ccRCC.
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Introduction
The receptor tyrosine kinases (RTKs) constitute a superfamily of
transmembrane proteins that relays signals from extracellular
growth factors into the cell. [1,2]
The TAM subfamily of RTKs contains the receptors Axl,
Tyro3, and Mer [3,4]. They have in common a unique
extracellular domain composed of two N-terminal immunoglob-
ulin-like domains and two fibronectin type III repeats similar to
the structure of neural cell adhesion molecules (NCAMs). The
TAM receptors share the same ligand, Gas6, the product of the
growth arrest-specific gene 6 [5,6]. Gas6, cloned from serum-starved
fibroblasts, is a member of the vitamin K-dependent family of Gla
proteins homologous to the blood coagulation protein S [7].
However, Gas6 is not believed to harbor any coagulation
properties [8,9]. Instead, Gas6 in general serve as a mitogen and
survival factor that protects cells from serum starvation-induced
apoptosis [10].
Adequate evidence supports the role of the Gas6/Axl system in
driving cell growth and survival in normal and cancer cells [4]. Axl
was originally cloned as a transforming gene in human chronic
myeloid leukemia and myeloproliferative disease [11,12], and
shown to transform NIH3T3 cells and render them tumorigenic in
vivo [12]. Since then, Axl overexpression and signaling has been
implicated in several human malignancies, such as colon [13],
breast [14], glioma [15], thyroid [16], gastric [17], melanoma
[18], lung cancer [19], and in renal cell carcinoma (RCC) [20]. A
more detailed role of Axl biology has been proven in glioma,
where loss of Axl signaling diminished glioma tumor growth [21],
and in breast cancer, where Axl drive cell migration, tube
formation, neovascularization, and tumor growth [22].
Recently, we have seen that Axl and Gas6 expression correlates
to survival in a large cohort of RCC patients [20]. Interestingly, we
found low Axl mRNA to independently correlate with substan-
tially longer patient survival. Furthermore, patients with low Axl
and high Gas6 mRNA levels as a combination had further
increased survival.
RCC is a common tumor of the kidney with poor prognosis.
Several RCC tumor types are present based on different
histopathological and specific genetic variations. Clear cell RCC
(ccRCC) represents the majority of RCCs and alteration in the von
Hippel-Lindau (VHL) tumor suppressor gene is one of the most
common genetic alterations occurring in about 80% of these cases.
The VHL protein function as an ubiquitin ligase and targets the
hypoxia inducible transcription factors HIF-1a and HIF-2a for
degradation. Loss of VHL function leads to a pseudo-hypoxic
response in ccRCC that conveys much of the disease progression.
[23,24]
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7575In the kidney, Gas6 and Axl are mainly expressed in glomeruli,
tubular endothelial and mesangial cells [20,25,26] and Gas6
functions as an Axl-specific autocrine growth factor in mesangial
cells [27–29].
In the present investigation, we used a cell based RCC model
system in order to explore the complex role of Gas6 and Axl in
RCC. Our results contribute to the understanding of the
multifaceted molecular biology of the disease.
Results
Active Axl/Gas6 System in ccRCC Tissue Biopsies
Axl was present in homogenized tissue lysates from a panel of
matched ccRCC patient biopsies and their respective unaffected
kidney cortex tissue counterparts (Fig. 1A). Since Axl phosphor-
ylation and activation occurs upon binding of its ligand Gas6 [30],
we investigated the phosphorylation status of Axl in the biopsies.
All three known Axl glycosylation isoforms (140, 120, and 104
kDa) [11,31] were phosphorylated with various intensities in
human ccRCC tissue (Fig. 1A; upper panel). Interestingly,
compared to total amount of Axl protein immunoprecipitated
(Fig. 1A; lower panel), the level of phosphorylation in the different
biopsies varied extensively. Some biopsies with low Axl protein
had very high phosphorylation status, e.g., lane seven, and vice
versa, some biopsies with high Axl protein expression showed no
or low phosphorylation level, e.g., lane two, three, and six (Fig. 1A).
Moreover, since Gas6 ligand only is functional and can
stimulate Axl properly when correctly c-carboxylated processed
by Vitamin K [32], we examined whether Gas6 was present and
c-carboxylated in the matched ccRCC biopsies. We found Gas6 to
be expressed and correctly c-carboxylated in vivo (Fig. 1B).
We also measured absolute expression levels of Axl and Gas6 in
the different biopsies using specific ELISA assay, and the
concentrations are given below each figure (Fig. 1A,B). Since the
Figure 1. Axl is phosphorylated and Gas6 is c-carboxylated in human ccRCC tissue. Homogenized tissue lysates from a panel (patient one
to eight) of matched ccRCC tissues and unaffected kidney cortex counterparts were used for Axl (A) and Gas6 (B) immunoprecipitation with specific
polyclonal antisera (#R042 towards Axl N-terminal; #005 towards Gas6) containing 50–100 mg total immunoglobulin molecules (about 0.5–1.0 mg
specific immunoprecipitating antibody). Pellets were separated on a 6% denaturing SDS-PAGE gel. Protein expression and posttranslational
modifications were verified with western blot analysis using Axl (Axl-C20; towards Axl C-terminal), Gas6 (R&D), phosphotyrosine (PY99) and Gla (M3b;
5 mM EDTA final) specific antibodies, respectively. Membranes were first immunoblotted for phosphotyrosine and Gla, respectively, and thereafter
stripped and reprobed for total Axl and Gas6. For each patient the matched samples are denoted: N (normal unaffected kidney cortex) and T (ccRCC
tissue). Absolute concentrations in the lysates measured by ELISA are depicted below each sample.
doi:10.1371/journal.pone.0007575.g001
Gas6 and Axl in RCC Cells
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1 mg specific immunoprecipitating antibody) the various Axl and
Gas6 concentrations detected by the ELISA assays could not be
reflected by the levels detected on western blot analysis (Fig. 1A,B).
Axl and Gas6 Expression in ccRCC 786-O Cells
In our attempt to study the biological role of Gas6 and Axl
signaling in a cell based model system, we first verified the
expression and functionality of Axl and Gas6 in the ccRCC
786-O cell line deficient in the VHL tumor suppressor protein.
Western blot analysis showed high expression levels of Axl protein
in these cells (Fig. 2A). However, no Gas6 protein could be found
neither with western blot on total cell lysate (data not shown) nor
with immunoprecipitation (Fig. 2B). In contrast to the results
obtained using western blotting, a weak expression of Gas6
mRNA in the same range as that of Gas6 mRNA in ccRCC
tumor could be detected using quantitative real-time PCR (qRT-
PCR; Table 1). The quantity of Axl mRNA in 786-O cells was
very high relative to Gas6 mRNA levels and relative to Axl
mRNA levels in the pair of matched normal and tumor RCC
tissues (Table 1). The relative expression of Axl mRNA was as
high as seen in the limited number of ccRCC tumors analyzed in
our previous study [20]. By employing VHL reconstituted 786-O
cells we were able to clarify the impact of functional VHL on Axl
and Gas6 expression. No difference in mRNA levels could be
detected in the three 786-O subclones (786-O wt, mock, and
VHL reconstituted; Table 1).
Gas6 Induces Axl Phosphorylation in ccRCC 786-O Cells
In order to verify functionality of our model system, the ability
of Gas6 to bind and activate Axl was determined by evaluating the
ligand-dependent phosphorylation of Axl in 786-O cells. Gas6
stimulated cells showed phosphorylated Axl, while TBS control
treated cells show no or markedly low basal Axl phosphorylation
levels (Fig. 2C,D). Using 400 ng/mL of Gas6 yielded saturated Axl
phosphorylation levels (compared to higher concentrations of
Gas6; Fig. 2C). Lower doses of Gas6 stimulation resulted in Axl
phosphorylation displaying a dose-response relationship (data not
shown). Gas6 stimulation timecourse revealed a peak of phos-
phorylated Axl levels between 5 and 10 minutes (Fig. 2D). Notably,
there was a 2-fold higher induction level of Gas6-dependent Axl
phosphorylation in cells grown in 1% FCS compared to cells
grown in 10% FCS (data not shown). Furthermore, we found a
modest increase in phosphorylated Erk levels after 10 min of Gas6
stimulation (Figure S1B). No influence of Gas6 stimulation on Akt
phosphorylation could be found (Figure S1A). Intriguingly, our
preliminary results suggested a dip in total Akt levels at 20 min of
Gas6 stimulation, which was a consistent observation that we
currently cannot explain (Figure S1A).
Gas6 Inhibits Migration and Cell-Viability of ccRCC 786-O
Cells Mediated through Axl
Migration. To examine the effect of Gas6 stimulation on
786-O cell migration, the chemotaxis-based Boyden chamber
migration assay was employed. A significant decrease in migration
Figure 2. Axl but not Gas6 is expressed in ccRCC 786-O cells and can be functionally active. Expression of Axl (A) and Gas6 (B) were
analyzed by western blot analysis using total cell lysate (tcl; Axl) and immunoprecipitate (Gas6) separated on an 8% reducing SDS-PAGE gel, and
using Axl (Axl-C20) and Gas6 (R&D) specific antibodies, respectively. Gas6 expression in 786-O cells, grown in conditioned medium with and without
vitamin K, was compared to expression in stably transfected Hek293 cells [51]. Gas6-dependent Axl phosphorylation was analysed in serum-starved
(1% FCS; 20 h) 786-O cells stimulated with various Gas6 concentrations for 10 min (C) and stimulated with 400 ng/mL Gas6 for up to 1 h (D). Total cell
lysate of stimulated cells were subjected to Axl immunoprecipitation with an in house Axl-specific polyclonal antibody (R042) and immune-
complexes were thereafter separated on 8% reducing SDS-PAGE and immunoblotted for phosphorylated Axl (PY99). The membranes were stripped
and reblotted for total amount of immunoprecipitated Axl (Axl-C20). Representative western blots are shown.
doi:10.1371/journal.pone.0007575.g002
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to mock stimulation (Fig. 3A).
In order to verify that the Gas6-dependent decrease of
migration was due to specific ligation and activation of the Axl
receptor by Gas6 we performed the migration experiment using
Axl knockdown cells. The abrogation of the Axl protein expression
was performed using Axl silencing RNA (siAxl). Axl protein
expression was undetectable by western blot analysis after silencing
compared to control cells transfected with scrambled siRNA
(siSCR; Fig. 3B). The mRNA levels of the Axl transcript was
decreased to approximately 7% of that of control transfected cells
(Fig. 3C). Gas6 stimulation (400 ng/mL) of Axl-knockdown cells
yielded no significant difference in migratory capacity compared
to mock-stimulated siAxl cells (Fig. 3D), verifying that the Gas6-
dependent inhibitory effect was mediated through the Axl receptor
and that Axl per se does not contribute to the migratory capacity of
786-O cells (Fig. 3D).
Viability. Using the tetrazole 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay, we examined the
metabolic activity as an estimation of 786-O cell-viability after
stimulation with Gas6. A modest but clear decrease in viability was
seen after 24 h of Gas6 stimulation (400 ng/mL) compared to
TBS control stimulated cells (Fig. 4A). Knockdown of Axl
expression did not by itself affect the viability of 786-O cells
(data not shown).
Table 1. Gas6 and Axl mRNA expression in a ccRCC kidney
and cell line.
Relative mRNA expression
j
786-O wt 786-O mock 786-O VHL RCC tumor RCC normal
Axl 0.962 1.307 1.047 0.270 0.104
Gas6 0.0011 0.0022 0.0011 0.0002 0.0007
jqRT-PCR measurement relative to human b2-microglobulin reference gene.
786-O wt, mock and VHL refers to ccRCC 786-O cells that are not transfected
(defective VHL), empty vector transfected (defective VHL) and VHL
reconstituted (functional VHL), respectively.
doi:10.1371/journal.pone.0007575.t001
Figure 3. Gas6-dependent Axl-mediated inhibition of ccRCC 786-O cell migration. The migratory capacity of 786-O cells upon Gas6
stimulation was analyzed using the Boyden chamber assay. (A) Gas6 stimulation (400 ng/mL) for 4 h decreases the migratory capacity of 786-O cells
to about 80% in comparison to that of mock treated cells. Verification of the Axl knockdown using siAxl and siSCR treated cells by either (B) western
blot analysis or (C) qRT-PCR as described in material and methods. (D) The inhibition of migration due to Gas6 stimulation was a consequence of
ligand specific activation of the Axl receptor as confirmed by repeating the migration experiment using the siAxl and siSCR treated 786-O cells. Each
experiment was conducted in triplicates, and the result out of three independent experiments is shown. Fig. 3B,C shows results from one
representative experiment.
doi:10.1371/journal.pone.0007575.g003
Gas6 and Axl in RCC Cells
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Axl System
We wanted to investigate the role of Axl in the mechanism of
invasion of 786-O cells, known to have high invasive potency. For
this purpose, we used the modified Boyden chamber assay in which
the cells have to invade a matrigel layer. We could not detect any
effect of Gas6 stimulation on the invasive phenotype of 786-O cells
in comparison to TBS control (Fig. 4B). Since it is previously shown
that Axl mediates invasion both in a Gas6-dependent [17,21] and
independent manner [33], we investigated the invasive phenotype
of Axl knockdown 786-O cells. However, we could not detect any
significant decrease of invasion of cells where Axl RTK expression
was silenced compared to normal cells (Fig. 4C).
Regulation of Axl Protein Expression in ccRCC 786-O Cells
Gas6-dependent Axl downregulation. Stimulation of
786-O cells with 400 ng/mL Gas6 for up to 6 h resulted in a
time-dependent down-regulation of Axl protein. After 6 h of Gas6
stimulation, the expression of Axl protein was almost undetectable
by western blot analysis (data not shown). The amount of Axl
protein was significantly decreased after 6 h of stimulation
compared to the first time-point and compared to mock
stimulated cells (Fig. 5A).
Axl protein level is inversely related to VHL
expression. As shown in Table 2 Axl mRNA levels was not
affected by introduction of wt VHL in the VHL deficient 786-O
cells. In contrast, when Axl protein levels were assessed in the
786-O subclones a considerable difference was detected. Axl
protein was decreased to about half in VHL reconstituted cells
compared to mock transfected or untransfected VHL defective
cells. Importantly, the Axl protein levels remained low also when
the VHL reconstituted cells were grown at hypoxia (1% oxygen)
and hence reactivate the hypoxic response due to stabilization of
HIF-2a (Fig. 5B). These results suggest that Axl is not a direct HIF-
2a gene target (HIF-1a is not expressed in 786-O cells [34,35])
Moreover, Axl protein expression was high in ccRCC cell lines
with defective VHL protein compared to Caki-2 [36], a ccRCC
cell line with papillary RCC characteristic and functional VHL
(Fig. 5C). Together, these results show that loss of VHL is
associated with elevated levels of Axl through a yet unknown post-
transcriptional mechanism.
Discussion
We demonstrate inhibition of migration and viability in ccRCC
786-O cells as a result of Gas6 signaling through the Axl RTK.
However, the highly invasive phenotype of these cells was not
affected by the Gas6/Axl system. So far, in most human cancers
where the biology of Gas6 and Axl has been studied, Axl is
believed to exert oncogenic effects [13–16,19–21,37,38], and a
combined increase of Gas6 and Axl expression correlate with
Figure 4. Gas6-dependent Axl-mediated effects on ccRCC 786-O cell viability and invasion. Viability of 786-O cells were analysed using
the MTT assay. (A) Stimulation of 786-O cells with 400 ng/mL Gas6 for 24 h resulted in a viability of about 80% in comparison to that of control
treated cells. (B) Invasion of 786-O cells using the modified Boyden chamber assay with a matrigel layer for analysis of invasive capacity was not
affected by Gas6 stimulation (400 ng/mL). (C) Axl expression per se did not contribute to the high invasive phenotype of 786-O cells, since the lack of
Axl expression did not result in any significant diminished invasive capacity. Each experiment was performed using at least triplicates and the result is
shown from three independent experiments.
doi:10.1371/journal.pone.0007575.g004
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with favorable prognosis has so far only been reported in human
breast cancer [39] and in RCC [20], which partly may be
explained by mechanisms presented here.
Our results are in large contradictory to the common picture of
Gas6 and Axl signaling. Gas6 has for instance been shown to
induce chemotactic migration [40–42], to be an autocrine growth
factor in glomerular mesangial cells [28,29], and to drive
Figure 5. Gas6- and VHL-dependent Axl protein expression in ccRCC 786-O cells. (A) Serum-starved 786-O cells (1% FCS; 20 h) were
stimulated with 400 ng/mL Gas6 or mock control for up to 6 h. Gas6-dependendent Axl protein down-regulation over time were verified with
western blot analysis on total cell lysate from treated cells using 8% reducing SDS-PAGE. Membranes were immunoblotted with Axl specific
antibodies (Axl-C20) and reprobed with b-actin specific antibodies (A5441) for relative quantification of Axl expression levels. Each experiment was
run in duplicates and the result of three independent experiments is shown. (B) Axl expression in 786-O mock (VHL defective) or VHL reconstituted
cells was analyzed in cells grown in either normoxia or hypoxia (1% O2) under serum starvation (1% FCS) for 48 h. VHL-dependent Axl expression was
verified using western blot analysis of total cell lysates of treated cells that were separated on an 8% reducing SDS-PAGE gel. Membranes were
immunoblotted with Axl-specific antibodies (Axl-C20) and with b-actin specific antibodies (A5441) for relative quantification of Axl expression levels.
The experiment was carried out using a minimum of triplicates. (C) Axl inverse correlation to functional VHL protein was further analyzed by
immunoblotting for Axl expression in total cell lysates of a panel of ccRCC cell lines with different VHL status. Equal amounts of total protein were
separated on an 8% reducing SDS-PAGE gel and membrane immunoblotted with Axl-specific antibodies (Axl-C20).
doi:10.1371/journal.pone.0007575.g005
Table 2. ccRCC tumor characteristics at time of nephrectomy and patient clinicopathological information.
Patient Sex (Age) TNM stage
j Grade
y Survival (months) Endpoint event
1 (86:05) M (77) 3 3 18 Death by disease
2 (88:12) F (56) 4 4 12 Death by disease
3 (87:22) M (42) 4 2 249 Alive with no signs of disease
4 (88.02) F (55) 4 2 37 Death by disease
5 (86:10) M (75) 1 3 33 Death by disease
6 (87:24) F (82) 3 3 103 Death by disease
7 (87:26) F (53) 1 2 245 Alive with no signs of disease
8 (08:07) F (77) 4 4 8 Death by disease
jAccording to the tumor-node-metastasis (TNM) classification system 2002 [53].
yAccording to Skinner nuclear grade [54].
doi:10.1371/journal.pone.0007575.t002
Gas6 and Axl in RCC Cells
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with the expression of Axl [19,38], and Gas6-dependent signaling
through Axl has been shown to promote invasion of glioma cells
[21]. However, in line with our results, Gas6 has also been shown
to have opposing effects by inhibiting VEGFR-A driven migration
specifically through the activation of Axl RTK [44].
Our results together with known literature imply that the
biology of Gas6 and Axl is complex and probably context-specific.
Perhaps in RCC, where high Gas6 expression correlate with
improved prognosis [20], Gas6 can be protective and retard
cancer progression by mechanisms, such as decreased migratory
potential and decreased viability. High Axl mRNA expression is in
itself negative for the outcome of RCC patients [20], and
prolonged Gas6 stimulation of 786-O cells leads to protein
down-regulation of Axl. However, our present data do not provide
an explanation how Axl by itself contribute to poor prognosis. It is
possible that the adhesion-like extra cellular region of the Axl
receptor with its ability to mediate homophilic interactions and
adhesion [45,46] can contribute to a more aggressive cancer
phenotype in vivo independent of Gas6 stimulation. Other putative
uncharacterized contributions of Axl in cancer progression can
also be discussed. For instance, Axl dependent signal transduction
and survival mediated by other heterophilic interactions has been
described [47].
Another key aspect of the pathogenesis of ccRCC is the loss of
expression of the tumor suppressor VHL protein resulting in pro-
angiogenic stimulus of the cancer cells due to increased expression
of VEGF and autocrine signaling. [24] Interestingly, we found an
association between expression of Axl protein and the tumor
suppressor VHL in 786-O cells. When a functional VHL protein
was introduced, Axl protein levels decreased to about half. No
difference could be found in Axl mRNA levels. Furthermore, Axl
is not a gene target of HIF-2a, since there was a VHL dependent
downregulation of Axl in cells grown in hypoxia as well. As
mentioned, Axl has been shown to affect neovascularization in
vitro, and loss of Axl expression in tumor cells blocks growth of
human neoplasms [22]. Perhaps, Axl on its own, by homophilic
interactions and by a kinase domain-dependent mechanism [45],
contribute to the disease-specific angiogenic program during VHL
loss in tumor cells in parallel with angiogenic factors such as
VEGF. Gas6 signaling via Axl on the other hand has been shown
to have inhibitory effects on the VEGFR-driven angiogenic
program [44]. One might therefore speculate that at high Axl
expression levels, increased Gas6 signaling through Axl could be
anti-angiogenic and beneficial. These interesting results indicate
that there is a need for further exploration of the role of Axl and
Gas6 in regulation of the angiogenic process in ccRCC and
moreover, to determine whether VHL function as an Axl-specific
ubiquitin ligase or regulates Axl protein expression level by
another unknown mechanism.
Our results demonstrate that the Gas6/Axl system plays a role
in RCC, and that Gas6 not always functions as a mitogenic growth
factor. Our results lay the ground for further investigation of the
complex biology of Axl and Gas6 in RCC and several other
diseases where this signaling pathway contribute to the patholog-
ical process.
Materials and Methods
Patient Biopsies
Tumor biopsies and normal kidney cortex tissues were taken
from ccRCC patients. The study was approved by the ethical
committee of Umea ˚ University and by the Institutional Review
Board. Each patient participated after providing informed written
consent. For detailed information see [20]. Clinicopathological
characteristics of patients and tumors are shown in Table 2.
Cell Culture and Reagents
The ccRCC cell line 786-O wt [48] (American Type Culture
Collection; LGC Standards AB) was maintained in DMEM
supplemented with 10% FCS and 1% penicillin and streptomycin
and 1% L-glutamine. The mock (pRC3) and VHL reconstituted
(WT-7) 786-O cell lines [49] were generous gifts from W.G.
Kaelin Jr. (Dana Farber Cancer Institute) and were maintained
in the same medium supplemented with the selective agent
G418 (0.8 mg/mL Geneticin; Roche Applied Science, Life
Technologies).
For evaluation of Gas6 expression in 786-O wt cells, cells were
grown in supplement of 10 mg/mL vitamin K (Konakion; Roche).
The ccRCC Caki-2 cell line [36], and the ccRCC SKRC -7, -17, -
21 (kindly provided by Dr. E. Oosterwijk (Radboud University
Mijmegen medical Center, The Netherlands), and SKRC-52 cell
lines [50] were maintained in the same medium as 786-O cells.
In hypoxia experiments, cells were grown in 1% oxygen in a
400 Hypoxia Workstation (Ruskinn Technology Ltd.; MORTEK
AS) connected to a Fuskinn gas mixer module.
Preparation of Recombinant Gas6
Recombinant human Gas6 was expressed and collected in
serum-free OPTIMEM as described previously [51]. Monoclonal
antibody affinity purified Gas6 was thereafter obtained (to be
described elsewhere). In experiments where Gas6 control is
designated mock, Gas6 in OPTIMEM was used for Gas6
stimulation (Gas6), and OPTIMEM harvested from mock-
transfected cells as control (mock). In experiments where Gas6
control is designated TBS, purified Gas6 was used for Gas6
stimulation (Gas6), and purification buffer as control (TBS).
Preparation of ccRCC Lysates
Removal of ccRCC patient biopsies was performed as described
[20]. To extract total protein, 200 mg of frozen biopsies were
crushed with a mortar and pestle in liquid nitrogen. Powdered
tissues were directly dissolved in ice-cold lysis buffer (1% Triton X-
100, 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, and
10%glycerol supplemented with 100 mMPMSF, 200 mMSodium
Orthovanadateand the proteaseinhibitorcocktail setIII (#539134,
Calbiochem, MERCK; according to manufacturer) containing
AEBSF-Hydrochloride, Aprotinin, Bestatin, E-64, Leupeptin and
Pepstatin A. Suspensions were then vortexed for 1 min and
thereafter incubated on ice for 45 min. Finally, the lysed
suspensions were homogenized with a polytron (IKA T 8 Ultra-
Turrax, IKA) at level 5 for 2615 s, centrifugated at 20 0006g at
4uC for 5 min, and clear supernatants were transferred to clean
tubes for storage on ice until analysis the same day (2/3 of sample
was used for immunoprecipitation and the remaining sample was
used for the ELISA assays).
Preparation of lysate from ccRCC cell lines was performed as
follows. Adherent cells were put on ice. Medium was removed and
cells were washed once in ice-cold PBS. Thereafter, ice-cold lysis
buffer (1% Triton X-100, 25 mM Tris-HCl pH 7.5, 150 mM
NaCl, 5 mM EDTA, and 10% glycerol supplemented with
100 mM PMSF, 200 mM Sodium Orthovanadate, and 200 mg/
mL Aprotinin) was added to the plate, and lysis was allowed for
20 min with agitation at 4uC. After centrifugation at 20 0006g for
1 min at 4uC, the clear supernatants were transferred to fresh
tubes and stored on ice until use on the same day for
immunoprecipitation and western blot analysis.
Gas6 and Axl in RCC Cells
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Lysates (volume of ccRCC tissue lysates was 500 mL respec-
tively) were pre-cleared with 10 mL pre-immune sera for 30 min at
4uC with rotation followed by incubation with 10 x excess protein
A-Sepharose (in relation to immunoglobulin G-binding capacity;
#10-1041, Invitrogen Corporation) for another 30 min. Immune
complexes were removed by centrifugation at 20 0006g for 1 min
at 4uC and the pre-cleared lysates were subsequently incubated
with polyclonal antisera containing 50–100 mg total immunoglob-
ulin molecules (about 0.5–1 mg of specific immunoprecipitating
antibody) for 1 h at 4uC with rotation followed by incubation with
10 x excess protein A-Sepharose for another 30 min. Immune
complexes were pelleted by centrifugation at 20 0006g for 1 min
at 4uC, and washed x 2 in ice-cold lysis buffer and finally x 1 in ice-
cold TBS-T (50 mM Tris-HCl pH 7.4, 150 mM NaCl and 0.1%
Tween 20). The immunoprecipitated protein was released by
dissolving the pellet in reducing SDS-PAGE sample buffer
(200 mM Tris-HCl pH 8.8, 60% sucrose, and Bromophenol blue
supplemented with dithiothreitol (DTT) to 10 mM final sample
concentration).
Antibodies used to immunoprecipitate Axl and Gas6 from
ccRCC total cell lysate or from human ccRCC biopsies, were
generated as rabbit polyclonal anti-Axl (Ig-fraction of an in-house
polyclonal rabbit antiserum denoted R042; towards Axl N-
terminal) or anti-Gas6 antibodies (Ig-fraction of an in-house
polyclonal rabbit antiserum denoted R05).
Western Blot Analysis
Protein samples were separated on an 8% SDS-PAGE gel and
the proteins were transferred from the gel onto a polyvinylidene
fluoride (PVDF) membrane (Pall Corporation; VWR International
AB). After blocking, membranes were incubated with the following
unlabeled primary antibody: anti-phosphotyrosine (pY99; sc-7020,
Santa Cruz Biotechnology), anti-Axl (C-20; towards Axl C-
terminal; sc-1096, Santa Cruz Biotechnology), anti-Axl
(#AF154; towards Axl N-terminal, R&D Systems), anti-Gas6
(AB885, R&D Systems), anti-c-carboxyglutamyl acid (anti-Gla;
M3b) [52], kind gift from Dr. Johan Stenflo), anti-b-actin (A5441,
Sigma-Aldrich). HRP-conjugated secondary antibodies were
obtained from DAKO. Chemiluminescence was developed with
Immobilon Western Chemiluminescent HRP Substrate (WBKL
S0500, Millipore) and traced with Fuji LAS 3000IR CDD camera,
and the signals were quantified with the Image Gauge program
(FUJIFILM, Science Lab 2003, version 4.1).
Quantitative Real-Time Reverse Transcription PCR
One-step multiplex quantitative real-time reverse transcription
PCR (qRT-PCR) was employed using primary tumor total RNA
and matched histopathologically non-malignant kidney cortex
tissue serving as a reference (commercial ccRCC tumor RNA of
nuclear grade 3; Ambion). The qRT-PCR analysis was employed
as described previously [20].
ELISA Assay for the Quantification of Axl and Gas6
Concentrations of sAxl and Gas6 protein ccRCC patient
material and their matched normal counterparts were estimated
using in-house developed sandwich ELISA assays specific for sAxl
and Gas6 as previously described [20].
siRNA Transfection
ccRCC 786-O cells were seeded in 60 mm plates 24 h
preceding transfection. Thereafter, cells were transfected with
siRNA targeting Axl (siAxl; sc-29769, Santa Cruz Biotechnology)
or scrambled control siRNA (siSCR; sc-37007, Santa Cruz
Biotechnology) using Lipofectamine
TM2000 (#11668-019, Invi-
trogen) in serum-free OPTIMEM (GIBCO, Invitrogen) for 5 h at
37uC. The medium was then replaced with conditioned DMEM
containing 10% FCS and cells incubated for another 24 h.
Transfected cells were then used in the Boyden chamber assay
(below) to analyze their migratory and invasive capacity.
Boyden Chamber Migration and Invasion
Boyden chambers with 24-wells (TranswellH Permeable Sup-
ports; Cole-Parmer; BergmanLabora AB) were used to evaluate
the migratory capacity of Gas6 or mock stimulated wt ccRCC
786-O cells siAxl and siSCR transfected cells. The chambers
consist of an upper and lower space separated by a microporous
polycarbonate membrane with a pore size of 8 mm. Membranes of
each chamber were incubated in serum-free medium for an initial
equilibrium period of 1 h. A cell concentration of 1610
6 cells/mL
was added to each migration (upper) chamber. Cells were allowed
to attach for 2 h and thereafter chemotaxis was induced by
addition of 10% FCS to the lower chamber. Simultaneously,
400 ng/mL Gas6 (final concentration) or mock control were
added to both the upper and lower chamber and the cells were
allowed to migrate from the upper compartment through the
membrane towards the lower compartment along the chemoat-
tractant gradient.
Migration was allowed for 4 h at 37uC. The chambers were
then cleaned with a cotton swap with 1 x PBS to remove the cells
left on top of the membranes. Migrated cells were fixed for 15 min
in 4% paraformaldehyde. Membranes were cut out with a needle,
put on a glass slide and finally the cells were stained with 496-
diamidino-2-phenylindole (DAPI; Vector Laboratories Inc.; IM-
MUNKEMI F&D AB). Migrated cells could be counted using
microscopy at 406magnification.
In the invasion assay, Boyden chambers were coated with 50 mL
of 12.5% growth factor reduced matrigel (#354230, BD
Bioscience) and incubated at 37uC for 1 h. A cell concentration
of 1610
6 cells/mL was added to each pre-incubated invasion
chamber and cells were allowed to attach for 2 h with no
chemoattractant. Thereafter, chemotaxis was induced by addition
of 10% FCS to the lower chamber. Simultaneously, 400 ng/mL
Gas6 (final concentration) or TBS control were added to both the
upper and lower chamber and the cells were allowed under 16 h
at 37uC to invade the matrigel and migrate. Cells were harvested
as described in the migration assay. In both migration and
invasion assay three representative fields were counted for each
membrane and each treatment condition was assayed in triplicate
and repeated three times.
MTT Assay
ccRCC 786-O cells were seeded in a 96-well plate at a density
of 2.5610
4 cells/mL for 24 h at 37uC. Thereafter cells were
treated with 400 ng/mL Gas6 or TBS control and incubation was
continued for another 24 h. Thereafter, MTT dye solution
(Promega Corporation; Promega Biotech) was added and
incubation continued for another 4 h. The assay was ended by
addition of Stop/Lys solution (Promega Corporation) followed by
incubation over night in a light-protected container at room
temperature. The absorbance generated was read using the
ELISA-plate (anthos 2020, anthos labtec instruments) reader at
595 nm using 690 nm as a reference.
Statistical Analyses
For statistical analysis comparing one condition to a normalized
value, the one sample t-test to a theoretical value was used.
Gas6 and Axl in RCC Cells
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experiment the unpaired t-test was employed. Data are presented
as the mean 6 SD. All statistical tests were two-sided, and the
significance level was set at 0.05. Statistical analyses were
performed using the GraphPad Prism software package (version
4.0c for Macintosh).
Supporting Information
Figure S1 Gas6-stimulated ccRCC 786-O cells display a modest
increase in phosphorylated Erk levels.
Found at: doi:10.1371/journal.pone.0007575.s001 (0.15 MB
PDF)
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